113-53-1 Usage
Chemical Properties
Pale Yellow Low Melting Solid
History
Described in the 1960s by the Czech company Sdruzeni Podniku pro Zdravotnickon Vyrobu; SPOFA (Spofa, 1962)
Uses
A tricyclic antidepressant.
Synthesis Reference(s)
Synthesis (Spofa, 1962): S-Benzylthiosalicylic acid is treated with polyphosphoric acid and the resulting cyclic ketone is reacted with 3-dimethylaminopropyl magnesium chloride to afford an alcohol which is dehydrated with sulfuric acid. Synthesis of dosulepin
Clinical Use
Dosulepin (also referred to as dothiepin) is a member of the TCA family and has similar clinical uses as amitrip- tyline, thus providing effective treatment of depression (Goldstein and Claghorn, 1980; Lancaster and Gonzales, 1989; Donovan et al., 1991) and also against pain (Feinmann et al., 1984; Caruso et al., 1987) and tinnitus. Like amitriptyline it has sedative properties, however its anti-muscarinic side-effects are less pronounced. Dosulepin is readily absorbed from the GI tract and extensively demethylated while undergoing a first-pass effect. Metabolic pathways include next to hydroxylation and N-oxidation steps, S-oxidation. Elimination half-lifes vary from 14 to 24 hours interindividually (Maguire et al., 1982; Yu et al., 1986; Ilett et al., 1993).
Check Digit Verification of cas no
The CAS Registry Mumber 113-53-1 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,1 and 3 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 113-53:
(5*1)+(4*1)+(3*3)+(2*5)+(1*3)=31
31 % 10 = 1
So 113-53-1 is a valid CAS Registry Number.
InChI:InChI=1/C19H21NS/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11-
113-53-1Relevant articles and documents
DOTHIEPIN AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS
-
Page/Page column 20-21, (2010/11/29)
The invention relates to dothiepin, metabolites of dothiepin, isomers of the same, and pharmaceutically-acceptable salts and prodrugs of the same; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.